MeiraGTx Holdings (MGTX) Liabilities and Shareholders Equity (2017 - 2025)
MeiraGTx Holdings (MGTX) reported Liabilities and Shareholders Equity of $244.4 million for Q4 2025, down 9.39% on a YoY basis from $269.8 million in Q4 2024, and up 29.01% quarter-over-quarter from $189.5 million in Q3 2025.
MeiraGTx Holdings (MGTX) Liabilities and Shareholders Equity (2017 - 2025) Analysis & Trends
MeiraGTx Holdings has reported Liabilities and Shareholders Equity for 9 years, with the latest figure at $244.4 million in Q4 2025.
- For the quarter ending Q4 2025, Liabilities and Shareholders Equity fell 9.39% year-over-year to $244.4 million; the trailing twelve-month figure through Dec 2025 stood at $856.6 million (down 25.19% YoY), and the FY2025 full-year result was $244.4 million, down 9.39% from the prior year.
- Liabilities and Shareholders Equity for Q4 2025 stood at $244.4 million, up from $189.5 million in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $339.7 million in Q1 2021, with the low at $189.5 million in Q3 2025.
- Historically, Liabilities and Shareholders Equity has averaged $282.2 million across 5 years, with a median of $293.8 million in 2023.
- Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity advanced 22.9% — and 2025, when it sank 36.74%.
- MeiraGTx Holdings' Liabilities and Shareholders Equity stood at $320.2 million in 2021, then retreated by 0.6% to $318.2 million in 2022, then advanced by 2.67% to $326.7 million in 2023, then slipped by 17.44% to $269.8 million in 2024, then decreased by 9.39% to $244.4 million in 2025.
- The last three Liabilities and Shareholders Equity figures came in at $244.4 million (Q4 2025), $189.5 million (Q3 2025), and $198.7 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 37.37 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 811.27 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 14.93 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.73 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 23.64 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 33.89 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 12.81 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 26.48 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 640.56 Mn |
| 10 | MeiraGTx Holdings | 910.47 Mn | 844.54 Mn | 74.89 Mn | 244.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 244.43 Mn |
| Sep 30, 2025 | 189.47 Mn |
| Jun 30, 2025 | 198.72 Mn |
| Mar 31, 2025 | 224.01 Mn |
| Dec 31, 2024 | 269.75 Mn |
| Sep 30, 2024 | 299.49 Mn |
| Jun 30, 2024 | 266.65 Mn |
| Mar 31, 2024 | 309.24 Mn |
| Dec 31, 2023 | 326.74 Mn |
| Sep 30, 2023 | 267.19 Mn |
| Jun 30, 2023 | 310.26 Mn |
| Mar 31, 2023 | 288.14 Mn |
| Dec 31, 2022 | 318.24 Mn |
| Sep 30, 2022 | 301.41 Mn |
| Jun 30, 2022 | 252.46 Mn |
| Mar 31, 2022 | 287.69 Mn |
| Dec 31, 2021 | 320.16 Mn |
| Sep 30, 2021 | 303.34 Mn |
| Jun 30, 2021 | 326.77 Mn |
| Mar 31, 2021 | 339.68 Mn |